CORT Quote, Financials, Valuation and Earnings

Moderna has a net margin of 13.07% compared to Corcept Therapeutics's net margin of -907.48%. Corcept Therapeutics's return on equity of 21.3% beat Moderna's return on equity of -29.23%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 93.68%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 92.62%. Given that Corcept Therapeutics has higher upside potential than Moderna, analysts believe Corcept Therapeutics is more attractive than Moderna.

Corcept Therapeutics has a beta of 0.215, which suggesting that the stock is 78.473% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are larger than Moderna quarterly revenues of $107M. Corcept Therapeutics's net income of $20.5M is higher than Moderna's net income of -$971M. Notably, Corcept Therapeutics's price-to-earnings ratio is 61.53x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 12.08x versus 3.02x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 13.07% compared to Corcept Therapeutics's net margin of 24.89%. Corcept Therapeutics's return on equity of 21.3% beat Nektar Therapeutics's return on equity of -133.07%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 93.68%. On the other hand Nektar Therapeutics has an analysts' consensus of $4.92 which suggests that it could grow by 694.42%. Given that Nektar Therapeutics has higher upside potential than Corcept Therapeutics, analysts believe Nektar Therapeutics is more attractive than Corcept Therapeutics.

Corcept Therapeutics has a beta of 0.215, which suggesting that the stock is 78.473% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.715%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are larger than Nektar Therapeutics quarterly revenues of $29.2M. Corcept Therapeutics's net income of $20.5M is higher than Nektar Therapeutics's net income of $7.3M. Notably, Corcept Therapeutics's price-to-earnings ratio is 61.53x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 12.08x versus 1.29x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 13.07% compared to Corcept Therapeutics's net margin of -60.08%. Corcept Therapeutics's return on equity of 21.3% beat Sarepta Therapeutics's return on equity of -20.94%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 93.68%. On the other hand Sarepta Therapeutics has an analysts' consensus of $100.92 which suggests that it could grow by 179.64%. Given that Sarepta Therapeutics has higher upside potential than Corcept Therapeutics, analysts believe Sarepta Therapeutics is more attractive than Corcept Therapeutics.

Corcept Therapeutics has a beta of 0.215, which suggesting that the stock is 78.473% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.365%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Corcept Therapeutics's net income of $20.5M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Corcept Therapeutics's price-to-earnings ratio is 61.53x while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 12.08x versus 1.82x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 13.07% compared to Corcept Therapeutics's net margin of -7.89%. Corcept Therapeutics's return on equity of 21.3% beat Supernus Pharmaceuticals's return on equity of 6.24%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 93.68%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 23.02%. Given that Corcept Therapeutics has higher upside potential than Supernus Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Supernus Pharmaceuticals.

Corcept Therapeutics has a beta of 0.215, which suggesting that the stock is 78.473% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.736, suggesting its less volatile than the S&P 500 by 26.408%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are larger than Supernus Pharmaceuticals quarterly revenues of $149.8M. Corcept Therapeutics's net income of $20.5M is higher than Supernus Pharmaceuticals's net income of -$11.8M. Notably, Corcept Therapeutics's price-to-earnings ratio is 61.53x while Supernus Pharmaceuticals's PE ratio is 28.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 12.08x versus 2.64x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.